{
    "nctId": "NCT00352378",
    "briefTitle": "Primary Chemotherapy With Adriamycin/Cyclophosphamide(AC) vs Taxotere/Xeloda(TX) for Stage II and III Breast Cancer",
    "officialTitle": "A Phase III Randomized Study of Primary Chemotherapy With Adriamycin/Cyclophosphamide(AC) vs Taxotere/Xeloda(TX) for Stage II and III Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 209,
    "primaryOutcomeMeasure": "pathologic complete remission",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* All patients must have histologically confirmed and newly diagnosed breast cancer: stage II and III breast cancer.\n* PET results will determine node positivity.\n* No prior hormonal , chemotherapy or radiotherapy is allowed.\n* No breast operation other than biopsy to make diagnosis is allowed.\n* Age:18-years and older, not pregnant pre-, and postmenopausal women with good performance status (ECOG 0-1)\n* Adequate hematopoietic function:\n\n  1. Absolute granulocyte count \\>=1500/mm3,\n  2. platelet \\>=100,000/mm3, Hemoglobin \\>=10 g/mm3\n* Adequate renal function: Serum creatinine \\<=1.5 mg/dl\n* Adequate hepatic function:\n\n  1. total bilirubin: \\<=1.5 mg/dl\n  2. AST/ALT: \\<=three times normal\n  3. Alkaline phosphatase: \\<=three times normal\n* Adequate cardiac function: normal or nonspecific EKG taken within 1 mo of enrollment\n\nExclusion Criteria:\n\n* Patients who received hormonal , chemotherapy or radiotherapy for breast cancer\n* Patients who underwent surgery for breast cancer\n* Patients who have history of cancer other than in situ uterine cervix cancer or nonmelanotic skin cancer",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}